AI주식인사이트AI Stock Insight
B

진원생명과학

011000KOSPI

55.8 / 100

Reference Date: 2026-09-08

Financial Score14.0 / 40
News Sentiment18.8 / 25
Momentum12.0 / 20
Disclosure11.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Jinwon Pharmaceuticals focuses on biopharmaceutical CDMO services and next-generation biopharmaceutical development. The CDMO business produces cGMP-grade plasmid DNA for gene therapies and DNA vaccines, while also advancing mRNA vaccine and therapeutic development through technology licensing. In new drug development, the company has completed clinical trials for DNA vaccines targeting MERS, Zika, and SFTS, and is expanding research through global partnerships.

Number of Employees

52people

Average Salary

70.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
1.19Industry Average 1.204.0Point

In line with industry avg

ROE
-81.98Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
59.91Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20251.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼23.3% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲4.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -61.4% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 75

Detailed Momentum

52-week position8.0Point

Near 52w high (100%, uptrend)

Current 2,670Won52-week high 2,67052-week low 534
1-month return3.0Point

1m 0% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

6 totalPositive 2Neutral 3Negative 1
  • Negative불성실공시법인지정2026-09-04
  • Neutral기타시장안내 (개선계획서 제출)2026-08-31
  • Positive[기재정정]주요사항보고서(유상증자결정)2026-08-24
  • Neutral반기보고서 (2026.06)2026-08-14
  • Neutral반기검토의견부적정,의견거절또는완전자본잠식사실발생2026-08-14